ATX Share Price Performance
Recent ATX News & Updates
No updates
Amplia Therapeutics Limited Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.017
- Gross Margin
- 94.43%
- Net Profit Margin
- -173.69%
- Debt/Equity Ratio
- 0%
Amplia Therapeutics Limited Competitors
About ATX
- Founded
- 2000
- Employees
- n/a
- CEO
- WebsiteView website
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Australian Market Performance
- 7 Days: -0.2%
- 3 Months: 5.5%
- 1 Year: 8.6%
- Year to Date: 5.1%
The market has been flat in the last week, however the Materials sector is down 4.2%. More promisingly, the market is up 8.6% over the past year. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading